Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp)

Journals

1. Pratap A, Grant D, Vegesna A, Tummalacherla M, Cohan S, Deshpande C, Mangravite L, Omberg L. Evaluating the Utility of Smartphone-Based Sensor Assessments in Persons With Multiple Sclerosis in the Real-World Using an App (elevateMS): Observational, Prospective Pilot Digital Health Study. JMIR mHealth and uHealth 2020;8(10):e22108 View
2. Rafiei R, Williams C, Jiang J, Aungst T, Durrer M, Tran D, Howald R. Digital Health Integration Assessment and Maturity of the United States Biopharmaceutical Industry: Forces Driving the Next Generation of Connected Autoinjectable Devices. JMIR mHealth and uHealth 2021;9(3):e25406 View
3. De Angelis M, Lavorgna L, Carotenuto A, Petruzzo M, Lanzillo R, Brescia Morra V, Moccia M. Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review. Journal of Clinical Medicine 2021;10(11):2328 View
4. Limmroth V, Bayer-Gersmann K, Mueller C, Schürks M. Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study. JMIR Formative Research 2022;6(3):e31972 View
5. Bittner B. Drug delivery improvements to enable a flexible care setting for monoclonal antibody medications in oncology - Analogue-based decision framework. Expert Opinion on Drug Delivery 2023;20(4):457 View
6. Farej R, Rametta M, La Rose A, Quillen A, McLeod K. A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector. Neurology and Therapy 2022;11(1):373 View